Written answers
Wednesday, 19 February 2025
Department of Health
Medicinal Products
Jen Cummins (Dublin South Central, Social Democrats)
Link to this: Individually | In context | Oireachtas source
209. To ask the Minister for Health when it is intended to provide free hormone replacement therapy; if people who have been charged will be reimbursed for this cost in January and February due to the promise that it would be implemented for free in 2025; and if she will make a statement on the matter. [6476/25]
Kieran O'Donnell (Limerick City, Fine Gael)
Link to this: Individually | In context | Oireachtas source
Menopause is an important health and wellbeing issue which has been prioritised as part of the Government’s commitment to improved women’s health outcomes. Much important work has been done in this area, driven by the Women’s Health Taskforce and the Women’s Health Action Plans, launched in 2022 and 2024.
The new Programme for Government: Securing Ireland’s Future continues to emphasise this important commitment to improving women’s health outcomes and experiences.
Budget 2025 announced the intention to fund the cost of HRT products prescribed to a woman to help manage the symptoms associated with all stages of menopause. This new HRT measure represents another step to widen access to menopause related treatments and services and follows on from all the other developments that have taken place over several years.
On 5th November 2024 the Health Insurance (Amendment) and Health (Provision of Menopause Products) Bill 2024 passed all stages in the Oireachtas and was subsequently signed into law.
This legislation means that where a woman has been prescribed a HRT product by her healthcare provider to alleviate the symptoms associated with all stages of menopause, the cost of the HRT medications or products will be met by the State. For the purpose of this measure, menopause means, in relation to a woman, the various stages for the treatment of menopause symptoms and includes perimenopause, post menopause, early menopause, premature menopause and medically induced menopause.
This measure will cover any HRT medications and products which are reimbursable by the HSE, which have been prescribed for the purposes of alleviating the symptoms of menopause. The cost of GP consultation fees and pharmacy dispensing fees are not included in the measure.
The Department of Health has engaged with both the Health Service Executive (HSE) and the Irish Pharmacy Union in relation to the practical rollout of this measure and is working to introduce this measure as soon as possible.
No comments